Irland - engelsk - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin; somatropin - powder and solvent for solution for injection - 1 milligram(s) - somatropin and somatropin agonists; somatropin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin; somatropin - powder and solvent for solution for injection - 1.4 milligram(s) - somatropin and somatropin agonists; somatropin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin; somatropin - powder and solvent for solution for injection - 1.6 milligram(s) - somatropin and somatropin agonists; somatropin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin; somatropin - powder and solvent for solution for injection - 1.8 milligram(s) - somatropin and somatropin agonists; somatropin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin; somatropin - powder and solvent for solution for injection - 2.0 milligram(s) - somatropin and somatropin agonists; somatropin

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl) - somatropin 5 mg in 1.5 ml - norditropin [somatropin (rdna origin) injection] is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone (gh). norditropin [somatropin (rdna origin) injection] is indicated for the treatment of children with short stature associated with noonan syndrome. norditropin [somatropin (rdna origin) injection] is indicated for the treatment of children with short stature associated with turner syndrome. norditropin [somatropin (rdna origin) injection] is indicated for the treatment of children with short stature born small for gestational age (sga) with no catch-up growth by age 2-4 years. norditropin [somatropin (rdna origin) injection] is indicated for the replacement of endogenous gh in adults with growth hormone deficiency (ghd) who meet either of the following two criteria: - adult onset (ao): patients who have ghd, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease

USA - engelsk - NLM (National Library of Medicine)

eli lilly and company - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl) - somatropin 5 mg in 5 ml - humatrope is indicated for the treatment of pediatric patients with: - growth failure due to inadequate secretion of endogenous growth hormone (gh), - short stature associated with turner syndrome, - idiopathic short stature (iss), height standard deviation score (sds) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, - short stature or growth failure in short stature homeobox-containing gene (shox) deficiency, - short stature born small for gestational age (sga) with no catch-up growth by 2 years to 4 years of age. humatrope is indicated for the replacement of endogenous gh in adults with gh deficiency. humatrope is contraindicated in patients with: - acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure due to the risk of increased mortality with use of pharmacologic doses of somatropin [see warnings and precautions (5.1)] . - pediatri

USA - engelsk - NLM (National Library of Medicine)

emd serono, inc. - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl) - somatropin 4 mg in 1 ml - serostim (somatropin) is indicated for the treatment of hiv patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. concomitant antiretroviral therapy is necessary. - acute critical illness growth hormone therapy should not be initiated in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure [see warnings and precautions (5.1)]. - active malignancy in general, somatropin is contraindicated in the presence of active malignancy. any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin. somatropin should be discontinued if there is evidence of recurrent activity [see warnings and precautions (5.3)] . - hypersensitivity serostim is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients. systemic hypersensitivity reactions have been reported with

Irland - engelsk - HPRA (Health Products Regulatory Authority)

international medication systems (uk) ltd - atropine sulfate - solution for injection - 100 microgram(s)/millilitre - belladonna alkaloids, tertiary amines; atropine

Irland - engelsk - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - atropine sulfate - solution for injection - 600 microgram(s)/millilitre - belladonna alkaloids, tertiary amines; atropine